Bridgebio Pharma, INC Form 4 insider transactions

Maricel Apuli, Chief Accounting Officer of BridgeBio Pharma, Inc., sold 2,000 shares of common stock on July 30, 2026 for $80.06 per share.

Andrea Ellis, a Director of BridgeBio Pharma, Inc., sold 17,167 shares of common stock on July 9, 2026 for $84.00 per share.

Jennifer E. Cook, a Director of BridgeBio Pharma, Inc., sold 148,589 shares of common stock on July 9, 2026.

Director Jennifer E. Cook reported transactions involving BridgeBio Pharma, Inc. common stock, including the acquisition of restricted stock units and the sale of shares under a 10b5-1 plan.

BridgeBio Pharma Director Hannah Valantine reported transactions involving common stock and stock options on June 22, 2026, including a grant of restricted stock units and sales under a 10b5-1 plan.

BridgeBio Pharma, Inc. reports a Form 4 filing detailing the acquisition of restricted stock units and stock options by Director Andrew Lo.

BridgeBio Pharma, Inc. Director Charles J. Homcy acquired restricted stock units and stock options in a transaction on June 22, 2026.

Director Eric Aguiar of BridgeBio Pharma, Inc. acquired restricted stock units and a stock option, reflecting ongoing equity incentives for key personnel.

BridgeBio Pharma director Ronald J. Daniels was granted restricted stock units and stock options on June 22, 2026, as disclosed in a Form 4 filing.

BridgeBio Pharma, Inc. reports a Form 4 filing detailing stock transactions by Director Andrea Ellis.

BridgeBio Pharma director Fred Hassan acquired restricted stock units and stock options, signaling continued commitment and potential future equity.

BridgeBio Pharma director James C. Momtazee acquired restricted stock units and a stock option, signaling continued commitment and potential future equity.

BridgeBio Pharma Director Frank McCormick reports acquisition of restricted stock units and stock options, with details on beneficial ownership adjustments.

BridgeBio Pharma Director Douglas A. Dachille reported the acquisition of restricted stock units and stock options, alongside indirect ownership of common stock.

BridgeBio Pharma, Inc. director Ali J. Satvat has reported the acquisition of restricted stock units and stock options, alongside the disposal of common stock.

BridgeBio Pharma Director Jennifer E. Cook has reported transactions involving the sale of common stock and the exercise of stock options, executed under a Rule 10b5-1 trading plan.

BridgeBio Pharma CEO Neil Kumar sold a portion of his holdings via a pre-arranged Rule 10b5-1 trading plan.

BridgeBio Pharma CEO Neil Kumar has sold a significant number of company shares through a pre-arranged trading plan, as disclosed in a Form 4 filing.

BridgeBio Pharma's President and CFO, Thomas Trimarchi, reported transactions involving company common stock, including shares withheld for tax obligations and sales executed under a 10b5-1 plan.

BridgeBio Pharma CEO Neil Kumar has reported transactions involving restricted stock units and common stock, including shares withheld for tax obligations.

BridgeBio Pharma's Chief Accounting Officer, Maricel Apuli, reported a transaction involving the withholding of shares for tax obligations.

BridgeBio Pharma Director Scott Randal W. reported transactions involving the sale of common stock and the acquisition of stock options.

BridgeBio Pharma CEO Neil Kumar reported the sale of 80,000 shares of common stock over two days in May 2026, executed under a pre-arranged Rule 10b5-1 trading plan.

BridgeBio Pharma's Chief Accounting Officer, Maricel Apuli, sold 2,000 shares of common stock on April 30, 2026, as part of a pre-arranged 10b5-1 trading plan.

BridgeBio Pharma CEO Neil Kumar has sold a significant number of company shares through a pre-arranged 10b5-1 trading plan, with transactions occurring on April 9th and 10th, 2026.

BridgeBio Pharma, Inc. President and CFO Thomas Trimarchi received a grant of 59,041 restricted stock units (RSUs) under the company's incentive plan.

BridgeBio Pharma's Chief Accounting Officer, Maricel Apuli, received a grant of 14,170 restricted stock units under the company's incentive plan.

BridgeBio Pharma's CEO, Neil Kumar, was granted 40,570 stock options and 104,313 restricted stock units as part of his compensation.

BridgeBio Pharma CEO Neil Kumar sold 80,000 shares of common stock across two trusts on March 12 and 13, 2026, under a pre-arranged 10b5-1 trading plan.

BridgeBio Pharma Director Hannah Valantine exercised stock options and subsequently sold an equal number of common shares under a pre-arranged 10b5-1 plan.